Tonix Pharmaceuticals (NASDAQ:TNXP) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(2.93) by 92.15 percent. The company reported quarterly sales of $2.80 million which missed the analyst consensus estimate of $3.08 million by 9.19 percent. This is a 29.81 percent decrease over sales of $3.99 million the same period last year.